|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 87.58 CHF | -0.40% |
|
-3.01% | +3.29% |
| Dec. 11 | Monte Rosa Closes Global License Agreement With Novartis | MT |
| Dec. 10 | Swiss Equities Extend Losses; KOF Global Economic Barometers Stable | MT |
| Capitalization | 199B 190B 176B 156B 281B 16,857B 312B 2,184B 809B 6,932B 747B 730B 30,316B | P/E ratio 2024 * |
18.1x | P/E ratio 2025 * | 15.5x |
|---|---|---|---|---|---|
| Enterprise value | 212B 202B 188B 166B 300B 17,984B 333B 2,330B 863B 7,396B 797B 779B 32,344B | EV / Sales 2024 * |
4.21x | EV / Sales 2025 * | 4.02x |
| Free-Float |
87.19% | Yield 2024 * |
3.79% | Yield 2025 * | 3.94% |
More valuation ratios
* Estimated data
More news
Last Transcript: Novartis AG
| NOVARTIS AG : Deutsche Bank remains Neutral | Dec. 10 | ZD |
| NOVARTIS AG : Jefferies remains Neutral | Dec. 10 | ZD |
| NOVARTIS AG : Deutsche Bank remains Neutral | Dec. 05 | ZD |
| HSBC Downgrades Novartis to Reduce, Price Target is $95 | Dec. 04 | MT |
| NOVARTIS AG : JP Morgan reiterates its Neutral rating | Dec. 03 | ZD |
More press releases
More news
| 1 day | -0.38% | ||
| 1 week | -3.01% | ||
| Current month | -6.01% | ||
| 1 month | -5.09% | ||
| 3 months | -10.95% | ||
| 6 months | -7.39% | ||
| Current year | +3.29% |
1 week
87.27
90.55
1 month
87.2793.99
Current year
83.63102.72
1 year
83.63102.72
3 years
72.84102.72
5 years
65.09102.72
10 years
65.09103.20
| Director | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 2018-01-31 | |
| Director of Finance/CFO | 59 | 2013-04-23 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 2022-05-15 |
| Manager | Title | Age | Since |
|---|---|---|---|
Charles Sawyers
BRD | Director/Board Member | 65 | 2012-12-31 |
Bill Winters
BRD | Director/Board Member | 63 | 2012-12-31 |
| Chairman | 68 | 2012-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 10.40% | 121 M€ | -.--% | - | |
| 5.57% | 20 M€ | +16.68% | - | |
| 3.79% | 2 M€ | -25.75% |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -0.39% | -3.01% | +2.01% | +17.60% | 199B | ||
| -0.44% | -4.07% | +36.30% | +226.05% | 717B | ||
| -1.73% | +0.61% | +17.35% | +103.57% | 492B | ||
| -1.74% | -2.55% | -5.43% | -11.39% | 353B | ||
| -0.74% | -1.18% | +15.29% | +38.97% | 308B | ||
| -1.24% | -1.60% | -4.43% | +37.36% | 252B | ||
| -0.84% | -0.94% | +0.08% | -32.35% | 232B | ||
| -0.33% | -1.04% | +3.30% | +27.40% | 208B | ||
| -0.85% | -1.74% | +0.47% | +29.65% | 147B | ||
| -1.33% | 0.00% | -11.91% | -52.20% | 143B | ||
| Average | -0.54% | -1.00% | +5.30% | +38.47% | 305.16B | |
| Weighted average by Cap. | -0.62% | -1.39% | +11.70% | +75.03% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 50.42B 48.08B 44.58B 39.55B 71.29B 4,275B 79.19B 554B 205B 1,758B 189B 185B 7,688B | 52.6B 50.17B 46.52B 41.26B 74.38B 4,460B 82.62B 578B 214B 1,834B 198B 193B 8,021B |
| Net income | 11.04B 10.53B 9.76B 8.66B 15.61B 936B 17.34B 121B 44.91B 385B 41.48B 40.56B 1,684B | 12.51B 11.93B 11.06B 9.81B 17.69B 1,061B 19.65B 137B 50.88B 436B 46.99B 45.95B 1,907B |
| Net Debt | 13.3B 12.68B 11.76B 10.43B 18.8B 1,127B 20.88B 146B 54.09B 464B 49.95B 48.84B 2,027B | 12.69B 12.1B 11.22B 9.95B 17.94B 1,076B 19.93B 139B 51.62B 442B 47.67B 46.61B 1,935B |
More financial data
* Estimated data
Employees
76,057
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-12-12 | 87.67 CHF | -0.31% | 1,295,403 |
| 24-12-11 | 87.94 CHF | -0.92% | 4,053,583 |
| 24-12-10 | 88.76 CHF | -0.69% | 3,171,761 |
| 24-12-09 | 89.38 CHF | -0.48% | 3,006,728 |
| 24-12-06 | 89.81 CHF | -0.63% | 2,468,013 |
Delayed Quote Swiss Exchange, December 12, 2024 at 05:57 am EST
More quotes
Sell
Buy
Mean consensus
HOLD
Number of Analysts
21
Last Close Price
99.44USD
Average target price
115.30USD
Spread / Average Target
+15.95%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NOVN Stock